- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00481936
Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary study objective of this Phase 1 trial was to determine the maximum tolerated dose (MTD) of VB6-845 and evaluate the safety and tolerability of VB6-845 when administered as a monotherapy intravenous (IV) infusion (over 3 hours), once weekly in 4-week cycles, to subjects with EpCAM positive advanced solid tumours of epithelial origin.
Secondary objectives included evaluating the pharmacokinetic profile and immunogenicity of VB6-845 and assessing exploratory efficacy of VB6-845.
Dose cohorts of 3-6 subjects with EpCAM positive advanced solid tumours of epithelial origin are to be entered into the study. The starting dose is defined as 1.00 mg/kg, which is 1/10 of the no observed adverse effect level (NOAEL) reached in preclinical studies. Doses are to be escalated according to the modified Fibonacci design until 2 out of 3 or 2 out of 6 subjects experienced a Dose Limiting Toxicity (DLT). The MTD is to be reached when <2 out of 6 subjects experienced a DLT. An additional 12 subjects are to be enrolled at the MTD for further characterization of VB6-845 at that level.
Regardless of dose cohort, subjects are to continue to receive treatment until an unacceptable toxicity occurred, all lesions completely disappeared or disease progression is determined.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tbilisi, Georgia
- Chemotherapy and Immunotherapy Clinic Medulla
-
-
-
-
-
Moscow, Russian Federation
- Moscow City Oncology Hospital #62
-
Moscow, Russian Federation
- Blokhin Cancer Research Centre, Department of Chemotherapy and Combined therapy
-
Moscow, Russian Federation
- Blokhin Cancer Research Centre, Department of Clinical Pharmacology and Chemotherapy
-
Moscow, Russian Federation
- Non state Institution of Ministry of Health "Central Clinical Hospital #2 named after N.A. Semashko" of Open-joint stock company "Russian Railways"
-
Yaroslavl, Russian Federation
- Yaroslavl Regional Clinical Oncology Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Disease Characteristics:
- The patient must have locally advanced and/or metastatic solid tumour of epithelial origin for which standard therapy has failed or does not exist;
- The patient must have immunohistochemically-confirmed EpCAM positive disease;
Patient Characteristics:
- The patient must be male or female 18 years of age or older;
- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and life expectancy ≥ 12 weeks
- The patient must have adequate organ function, as defined by the protocol
- Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the first dose of the study drug;
Other:
- The patient must be able to understand and willing to sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
- The patient must be willing and able to comply with scheduled visits, the treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- The patient has had treatment with any investigational agent within 4 weeks, or treatment with radiation therapy to a visceral organ, immunotherapy, biological therapy, or chemotherapy within 2 weeks prior to the first dose of study medication
- The patient has not adequately recovered from the toxic effects of previous therapy, except treatment-related anemia otherwise meeting the inclusion requirements stated above in inclusion number 5 or alopecia;
- The patient has known clinically significant brain metastases or leptomeningeal disease (baseline computed tomography [CT] or magnetic resonance imaging [MRI] of the brain is only required if there is clinical suspicion of central nervous system involvement);
- The patient has experienced a previous significant hypersensitivity reaction;
- The patient has known acquired immune deficiency disease or has active hepatitis virus C (HVC) or active hepatitis virus B (HVB);
- The patient is pregnant or breast feeding; female patients will be required to be surgically sterile, agree to use double barrier contraception, or commit to abstinence during the period of therapy; male patients will be required to be surgically sterile, use double barrier contraception, or commit to abstinence during the period of therapy
- The patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness or social situations that would limit compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalating
Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met. Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33. |
Intravenous infusion once weekly for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the maximum tolerated dose of VB6-845 and to evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV infusion
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the pharmacokinetics, immunogenicity and exploratory efficacy of VB6-845
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Wendy Cuthbert, Sesen Bio, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VB6-845-01-I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Glandular and Epithelial
-
Catalysis SLRecruitingNeoplasms | Carcinoma | Neoplasia; Intraepithelial, Cervix | Glandular Neoplasms | Epithelial NeoplasmCuba
-
Providence Health & ServicesCelldex TherapeuticsEnrolling by invitationMalignant Epithelial NeoplasmsUnited States
-
Providence Health & ServicesActive, not recruitingMalignant Epithelial NeoplasmsUnited States
-
Genentech, Inc.CompletedEpithelial Tumors, MalignantSpain, United States
-
Synermore Biologics Co., Ltd.Synermore Biologics USA LimitedActive, not recruitingSolid Tumor | Epithelial CarcinomaUnited States
-
Vall d'Hebron Institute of OncologyBanc de Sang i TeixitsRecruiting
-
Institut CurieRecruiting
-
Akamis BioMerck Sharp & Dohme LLCRecruitingStudy of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY)Metastatic Cancer | Epithelial TumorUnited States, United Kingdom
-
Oslo University HospitalCompleted
-
Yale UniversityCompletedAdenomaUnited States
Clinical Trials on VB6-845
-
Qilu Pharmaceutical Co., Ltd.RecruitingNon-Muscle Invasive Bladder CancerChina
-
Sesen Bio, Inc.CompletedBladder CancerUnited States, Canada
-
Sesen Bio, Inc.CompletedUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder TumorsUnited States, Canada
-
Chong Kun Dang PharmaceuticalCompletedHypogonadismKorea, Republic of
-
Vanderbilt UniversityMallinckrodtCompletedPulmonary Vascular DisorderUnited States